Effects of WAL 801 CL (Epinastine hydrochloride) on Actual Driving Performance.

概要

論文の詳細を見る
The Effects of the new non-sedating H1-receptor antagonist, WAL 801 CL (Epinastine hydrochloride), was investigated in 12 healthy male volunteers by a randomized double-blind, cross-over design in comparison with d-chlorpheniramine and placebo on driving performance using on-the-road study of the most suitable method. The extent of sleepiness on driving was evaluated from continuously recorded electroencephalogram (EEG), eye movement and steering performance and the Stanford Sleepiness Scale (SSS).As the results, the achieved duration of continuous driving, the alpha activity ratio in EEG, the frequency of slow blinking and the SSS were not significantly different between the WAL 801 CL group and the placebo group. In the d-chlorpheniramine group, on the other hand, 6 out of 12 subjects could not complete 120min continuous driving, and the other parameters all showed significantly higher values than those of the WAL 801 CL group and the placebo group, indicating the central nervous system depressant action of d-chlorpheniramine during driving.This study suggests that WAL 801 CL is a new non-sedating H1-receptor antagonist without any influence on the overall driving ability.
一般社団法人日本臨床薬理学会の論文